We compared the clinical characteristics and outcomes of, and the bacterial genotypes in, patients with bacteraemia due to heteroresistant vancomycin-intermediate Staphylococcus aureus (hVISA) and vancomycin-susceptible S. aureus (VSSA).
Introduction
Methicillin-resistant Staphylococcus aureus (MRSA) infection is associated with long hospital stay, high hospitalization costs, and increased morbidity and mortality. 1, 2 Vancomycin, a glycopeptide antibiotic introduced .50 years ago, is regarded as the mainstay of treatment for MRSA infections. The emergence of vancomycinintermediate S. aureus (VISA) and heteroresistant VISA (hVISA) has threatened the rank of vancomycin as the frontline antibiotic in these infections. Defined as the presence of subpopulations (typically at a rate of 1 organism per 10 5 -10 6 ) of MRSA with intermediate vancomycin resistance, hVISA was first reported in Japan in 1997, and since that time it has been found in clinical MRSA isolates throughout the world. 3 -8 The clinical significance of hVISA infection remains unclear due to variations in study populations and testing # The Author 2012. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com J Antimicrob Chemother 2012; 67: 1843 -1849 doi:10.1093/jac/dks131 Advance Access publication 25 April 2012 methodologies, and possible selection bias among cases with less favourable outcomes. 9, 10 Despite this, persistent infection and vancomycin treatment failure were commonly associated with hVISA infection. 10 -14 Isolates from previous reports were collected at various timepoints relative to antimicrobial therapy. For isolates collected after a substantial exposure to antimicrobial therapy, hVISA may be a result of treatment failure rather than the cause of treatment failure. 9, 10 Therefore, expression of the hVISA phenotype from initial clinical isolates rather than subsequent isolates may be more clinically relevant to the evaluation of the clinical impact of the hVISA phenotype on patient outcome.
The objective of the present study was to compare the clinical characteristics and outcomes of, and the bacterial genotypes in, consecutive patients with hVISA and vancomycin-susceptible S. aureus (VSSA) bacteraemia. All bloodstream isolates for identification of hVISA phenotype were obtained on the first day of bacteraemia and hVISA phenotype was explored by population analysis profiling (PAP).
Patients and methods

Study design and patients
From August 2008 to September 2010, data were collected as part of a prospective cohort study of S. aureus bloodstream infection at Asan Medical Center, Seoul, Korea. Patients with clinical infections and who yielded one or more blood cultures positive for S. aureus were identified by a daily search of the microbiology laboratory database. Patients younger than 18 years or who had polymicrobial infections were excluded. Only the first episode of bacteraemia was included in the analysis to ensure independence of observations. All MRSA isolates obtained on the first day of bacteraemia were stored for further testing. Attending physicians were blinded to the presence of hVISA infection. This study was approved by the Asan Medical Center Institutional Review Board.
Clinical data and definitions
The following data were obtained for all patients: age; gender; presence of pre-existing comorbidities; Charlson comorbidity score; intensive care unit stay at the onset of bacteraemia; mode of acquisition; primary site of infection; presence of septic shock; Acute Physiology and Chronic Health Evaluation II (APACHE II) score; history of recent surgery; receipt of cancer chemotherapy; receipt of immunosuppressive therapy (≥10 mg/day prednisone or equivalent for ≥14 days, or any dose of another immunosuppressant agent); previous vancomycin therapy; presence of a prosthetic medical device; and antibiotic treatment. Clinical outcomes were also assessed, including the presence of persistent bacteraemia (≥7 days), metastatic infection, death, infection-attributable death and length of hospital stay. Death was attributable to MRSA bacteraemia if blood cultures were positive for MRSA at the time of death or if death occurred before resolution of the signs and symptoms of MRSA bacteraemia without another explanation. 15 Length of hospital stay after infection was calculated from the first blood culture positive for S. aureus until discharge or death.
Laboratory and molecular methods
All blood cultures were analysed using BACTEC 9240 (Becton Dickinson, USA) and all S. aureus isolates were identified by standard methods. The MIC of vancomycin was determined using the Etest (AB Biodisk, Solna, Sweden) according to the manufacturer's instructions. Broth microdilution was performed according to the methods of the CLSI using the current susceptibility breakpoints of ≤2 and 4 -8 mg/L to define VSSA and VISA isolates, respectively. 16 Vancomycin MICs were determined by blinded observers who had no knowledge of clinical outcomes. Except where noted, all vancomycin MIC values in the text were defined according to Etest.
All MRSA isolates were assessed by the PAP-area under the curve (PAP-AUC) method, using the technique of Wootton et al. 17 An isolate was identified as hVISA if the ratio of the AUC of the test isolate to that of the reference strain (Mu3; ATCC 700698) was ≥0.9. The presence of 41 bacterial virulence factors, including adhesins, toxins, agr subgroup I-IV and other genes, was examined by multiplex PCR, as described elsewhere. 18 -21 The staphylococcal cassette chromosome mec (SCCmec) types were identified using a previously described method. 22 Multilocus sequence typing (MLST) was achieved as described previously. 23, 24 Statistical analysis All statistical analyses were performed using SPSS for Windows, version 14.0 (SPSS, Inc., Chicago, IL, USA). Categorical variables were compared by the x 2 test or Fisher's exact test, and continuous variables were compared using the Student's t-test or Mann-Whitney U-test, as appropriate. All variables significant upon univariate analysis, hVISA status and vancomycin MIC were included in a logistic regression model to identify independent risk factors for all-cause mortality. All variables that were significant in univariate analysis were subjected to logistic regression modelling to identify independent risk factors for the presence of hVISA. All tests of significance were two-tailed, and a P value of ≤0.05 was considered to be significant.
Results
Clinical characteristics
A total of 268 patients with MRSA bacteraemia were prospectively enrolled during the study period (August 2008 to September 2010). Initial blood isolates from all patients were available for analysis. Based on PAP-AUC ratios, 101 isolates (37.7%) had the hVISA phenotype and 167 isolates (62.3%) had the VSSA phenotype. Table 1 shows the clinical characteristics and outcomes of patients with hVISA and VSSA bacteraemia. Patients with hVISA bacteraemia were more likely to be male, to have spent time in an intensive care unit, and to have been prescribed immunosuppressive therapy and prior vancomycin therapy. Patients with hVISA bacteraemia were less likely to have a haematological malignancy. Table 2 compares the vancomycin MICs and the frequencies of drug resistance to several non-b-lactam antibiotics of our hVISA and VSSA isolates. A significant association was evident between increasing vancomycin MIC (irrespective of the method used to estimate MIC) and the presence of hVISA (P,0.001). Isolates with hVISA were more likely to be resistant to several non-b-lactam antibiotics, including clindamycin, ciprofloxacin, rifampicin and trimethoprim/sulfamethoxazole. Table 3 shows the genotypic characteristics of our hVISA and VSSA isolates. ST72 (where ST stands for sequence type) was more common among VSSA isolates than hVISA isolates (47/166 versus 17/101; P ¼ 0.03) and ST239 was more common in hVISA isolates than VSSA isolates (9/101 versus 3/166; P ¼ 0.01).
Microbiological and genotypic characteristics
Park et al. . A trend towards a higher frequency of persistent bacteraemia and metastatic infection and longer hospital stays in hVISA patients was evident, but this was not statistically significant (Table 1 ).
Univariate analysis indicated that age, Charlson comorbidity index, APACHE II score, receipt of immunosuppressive therapy and staying in an intensive care unit were associated with allcause mortality. Thus, we used these variables, the presence of hVISA and the vancomycin MIC value in the logistic regression modelling. Multivariate analysis indicated that age [adjusted OR (aOR), 1.02; 95% CI, 1.002 -1.05], Charlson comorbidity index (aOR, 1.21; 95% CI, 1.07 -1.38) and APACHE II score (aOR, 1.06; 95% CI, 1.03-1.10) were independently associated with all-cause mortality. Neither the presence of hVISA nor the vancomycin MIC was significantly associated with increased mortality (Table 4) .
Factors associated with the presence of hVISA
Univariate analysis indicated that several clinical and microbiological factors were significantly associated with the presence (Figure 1a) . No significant difference in vancomycin MIC distribution, the proportion of patients with endocarditis or osteomyelitis, or any other baseline characteristics, was apparent in patients with initial mean trough levels of ,15 mg/L and those with initial mean trough levels of ≥15 mg/L (data not shown). Infection-attributable mortality did not differ in all patients with MRSA bacteraemia after stratification by initial vancomycin trough level and hVISA status (Figure 1b) . Comparison of hVISA and VSSA bacteraemia 1847 
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Discussion
The present work is one of the largest prospective cohort studies to compare the microbial genotypes of isolates from, and the clinical features and outcomes of, bacteraemia patients with hVISA and VSSA. When the initial blood isolate was tested for hVISA phenotype by the PAP -AUC method, more than one-third of all isolates had the hVISA phenotype. We found that patients with hVISA and VSSA infections had similar mortality rates, consistent with the data of a recent meta-analysis. 10 A vancomycin MIC of ≥2.0 mg/L is often used to predict the presence of the hVISA phenotype. 4, 12, 25 After adjusting for this robust risk factor for hVISA, we identified other baseline characteristics as independent risk factors for hVISA presence. In particular, rifampicin resistance of the initial blood isolate (before initiation of treatment) was independently associated with the hVISA phenotype. A previous study found that rifampicin resistance developed more frequently in patients with hVISA than in those with VSSA (44% versus 5.9%; P,0.001) during treatment of bacteraemia. 4 A more recent study found that 71% of 38 VISA clinical strains had rpoB mutations and 95.6% of rifampicinresistant mutants had the VISA or hVISA phenotype. 26 This suggests that an rpoB mutation may play a role in decreased vancomycin susceptibility. In addition, we found that prior vancomycin therapy was independently associated with hVISA presence, consistent with the data of previous studies. 3, 8, 14, 27, 28 A more recent study showed that vancomycin selected for hVISA during the therapy of experimental endocarditis due to VSSA. 29 These findings support the hypothesis that vancomycin exposure has the potential to select for hVISA. Finally, prescription of immunosuppressive therapy was an independent predictor of the presence of hVISA, an association not identified in previous studies. 8, 12, 30 We used PCR to assay the expression of many virulence factors and found significant differences in expression of several such genes between the hVISA and VISA groups. However, these differences were small and probably of limited clinical relevance. Although ST239 was not a major clone in our patients, the hVISA phenotype was more common in ST239 than in other STs (9/12 versus 92/255; P ¼ 0.01). Interestingly, a recent report also found that the hVISA phenotype was more common in ST239 than in other STs (46/311 versus 0/77; P,0.001). 8 We found that an initial mean vancomycin trough level of ,15 mg/L was associated with an increased frequency of persistent bacteraemia, and such an association was more pronounced in patients with hVISA than with VSSA. Recently, Kullar et al. 31 reported a significant association between an initial vancomycin trough level of ,15 mg/L and vancomycin failure. Therefore, our present data and those of Kullar et al. 31 support the current recommendation of targeting higher vancomycin trough levels (15 -20 mg/L) in patients with MRSA bacteraemia. 32 In addition, our results suggest that maintenance of this target may be more effective in patients with hVISA bacteraemia than in those with VSSA bacteraemia.
Our present study has limitations. First, the prevalence of hVISA bacteraemia in our single-institution study was 37.7%, which is higher than what has been reported in other studies. 6,8 -12,14,33 We did not use PFGE to type MRSA blood isolates, and we thus could not evaluate the possibility that clonal relationships may exist among some isolates. Second, initial vancomycin trough concentrations were not measured in one-fifth of the patients who received vancomycin as initial treatment. However, we believe that this did not affect the results, because treating physicians were blinded to hVISA status, and the proportions of patients with an initial trough concentration measured for the hVISA and VSSA groups were similar.
In summary, our present study of patients with MRSA bacteraemia yield several key findings. A vancomycin MIC of ≥2 mg/L, rifampicin resistance, prior vancomycin therapy and prescription of immunosuppressive therapy were all independently associated with the presence of the hVISA phenotype. No significant difference in terms of clinical outcomes of patients with VSSA and hVISA was evident, but our data suggest that targeting a vancomycin trough level of 15 -20 mg/L may benefit patients with hVISA bacteraemia.
